Vacancy Machine Learning to support interventional MRI
We are looking for a team member to further develop Machine Learning to support interventional MRI.
We are looking for:
For our ongoing product development we are seeking a candidate with experience in AI and machine learning with applications in liver embolization procedures. Candidate has a Master in (Bio)medical Engineering, Medicine or Physics. Ideally, candidate should:
- have experience in medical imaging and/or image analysis in broader sense;
- be able to work in a development team using online commucation tools;
- have experience in interfacing with and operating of MRI platforms;
- be excited by opportunities provided by AI and Machine learning;
- be used to work in a dynamic team in a international business environment with English and German as routine communication tools.
We offer you:
Cooperation in a top team, international setting and access to all university facilities;
- embedding in the dynamic AI group of Daniel Truhn at the RWTH Aachen, which is one of the biggest clinical centers in Germany;
- the chance to obtain a PhD degree at the RWTH;
- a high degree of independence and opportunities for further training;
- chances to develop professionally in a fast growing company and interacting with our international business and research partners;
- interesting remuneration (annually 54.000 € ) and an attractive benefit package;
- employment status: fulltime and partly from distance.
More information and application to:
Paul J.A. Borm, co-founder and CTO
+31 6 4172 5351 or email@example.com
Daniel Truhn, MD, Radiology RWTH- Aachen
+49 1703 2158 06 or firstname.lastname@example.org
Nano4Imaging GmbH (N4I) was founded in January 2011 and is now based in Dusseldorf (Germany). Our company vision is to enable minimal invasive procedures for MRI, and to do this we produce and market MRI compatible instruments, both under FDA and CE label, and markers that allow guidance and visibility of other medical devices. N4I products have clinical users in congenital heart disease, pulmonary hypertension and we are now also entering interventional radiology procedures such as liver cancer therapy.